BOCA RATON, Fla., June 15, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it will attend the Cystic Fibrosis Research Institute’s (CFRI) 36 National Cystic…Read More
First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference July 2830
